Poxel Logo

Poxel | POXEL - Profile, Filings, Stock Info & Investor Relations Data

Poxel | POXEL
Filings & Investor Relations Data
Login to Watchlist

Create a free account or log in.

Country
France
Founded
2009
Poxel (POXEL)

About Poxel

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterium-modified thiazolidinedione (dTZD) platforms targeting chronic and rare metabolic diseases. Poxel’s first-in-class lead product, TWYMEEG® (Imeglimin), that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.

Employees

53

Market Presence

Worldwide

Headquarters

259 AVENUE JEAN JAURES
69007, LYON
France

Poxel (POXEL)
Key Financial Data

AI-Powered Financial Insights Coming Soon

We are currently processing the filings for this company to provide automated financial statement analysis, key ratios, and risk summaries. Please check back later!

Unlock Full Company Insights & AI Chat

Create a free account or log in to add companies to your watchlist, access more data, and chat directly with filings using our AI assistant (as shown!).

Poxel (POXEL)
Filings & Annual Reports
Chat with AI, summarize, and extract data from processed filings! Look for the 'View & AI' button.

Quick Filters:

Advanced Filters

View all types
Filing Information Actions

Insider Trading Activity

N/A (Other)
Buy EUR 0.00 EUR 0.00 29.01.24

Poxel (POXEL)
Stock & Investor Information

ISINs

FR0012432516

LEI

9695003OIX0T7NX72N26

Stock Exchange Listings

Euronext Paris

Primary Stock Exchange Listing

View Poxel on main exchange

Industry Classification